Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Phase 2 Completed 48 enrolled Armata Pharmaceuticals, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

A phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 administered in subjects with non-cystic fibrosis bronchiectasis and chronic pulmonary Pseudomonas aeruginosa infection.

Timeline

Start: 2023-01-10
Primary completion: 2024-07-17
Completion: 2024-08-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AP-PA02	Other / unclassified	—	Inhaled

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Summary

Timeline

Drugs

Indications